4500 Health Care

UCB SA Monitor

UCB SA Annual Report 2017
CR Monitor Issue: 
2018/0611
Company covered: 
UCB SA
Period End: 
31 December, 2017
Report issued on 19 June 2018 covered the following practice issues:
Pronouncements
Early adoption of IFRS 15 "Revenue from contracts with customers" using a full retrospective approach.
Pronouncements
Enhanced disclosure in respect of the future impacts of IFRS 16 "Leases".
Change
Fair value of previously held interest in business acquired taken into account in calculation of goodwill.
Pronouncements
Presentation of a reconciliation of movements in liabilities arising from financing activities on adoption of amendment to IAS 7 "Statement of cash flows".
Change
Discussion of key audit matters included in the auditors' report.
Change
Extended disclosure of principal risks including identification of a new risk factor.

Qiagen NV

Qiagen NV Annual Report 2017
CR Monitor Issue: 
2018/0602
Company covered: 
Qiagen NV
Period End: 
31 December, 2017
Report issued on 06 June 2018 covered the following practice issues:
Pronouncements
Extended discussion in respect of IFRS 15.
Change
Disclosure of impact of changes in US tax laws.
Change
Detailed disclosure of multi-tranche bond issue.
Change
Auditors identify bond issue as a key audit matter.

Roche Holding Ltd Monitor

Roche Holding Ltd Annual Report 2017
CR Monitor Issue: 
2018/0521
Company covered: 
Roche Holding Ltd
Period End: 
31st December 2017
Report issued on 29 May 2018 covered the following practice issues:
Pronouncements
Extended disclosure in respect of the future impacts of new accounting standards.
Change
Additional information disclosed in respect of provisions.
Change
Disclosure of IFRS 5 information linked to business disposals.
Change
Change in presentation of cash flows from investing activities.
Change
Calculation of goodwill linked to step acquisitions takes into account fair value of previously held interests.
Change
Newly acquired investment in associate accounted for using the equity method.

Smith & Nephew Plc Monitor

Smith & Nephew Plc Annual Report Year
CR Monitor Issue: 
2018/0517
Company covered: 
Smith & Nephew Plc
Period End: 
31 December, 2017
Report issued on 22 May 2018 covered the following practice issues:
Pronouncements
Disclosure of changes in liabilities arising from financing activities in line with amendment to IAS 7 "Statement of cash flows".
Pronouncements
Inclusion of discussion in respect of new accounting standards IFRS 15 and IFRS 9.
Change
Discussion of key audit matters included in audit report.
Change
Business restructuring disclosed as post balance sheet event.
Change
Enhanced risk disclosures including additional information in respect of principal risks.
Restatement
Restatement of intangible asset amortisation without explanation.

GlaxoSmithKline plc Monitor

GlaxoSmithKline plc Annual Report 2017
CR Monitor Issue: 
2018/0508
Company covered: 
GlaxoSmithKline plc
Period End: 
31 December, 2017
Report issued on 08 May 2018 covered the following practice issues:
Pronouncements
Extended disclosure in respect of the future impacts of new accounting standards including quantification.
Change
Expanded disclosure of Non IFRS performance measures.
Change
Extended disclosure of principal risks including identification of new risk factor.
Change
Change in calculation of segment profit results in restatement of prior year figures.
Change
Change in disclosure in audit report in respect of director and auditor responsibilities.

Merck KGaA Monitor

Merck KGaA Annual Report 2017
CR Monitor Issue: 
2018/0415
Company covered: 
Merck KGaA
Period End: 
31 December, 2017
Report issued on 16 April 2018 covered the following practice issues:
Restatement
Finalisation of prior year provisional business combination amounts.
Pronouncements
Disclosure of the future impacts of new standards yet to be adopted including IFRS 9 "Financial instruments" and IFRS 15 "Revenue from contracts with customers".
Change
Audit report enhanced by inclusion of key audit matters.
Change
Segment disclosures extended.

Novozymes A/S Monitor

Novozymes A/S Annual Report 2017
CR Monitor Issue: 
2018/0318
Company covered: 
Novozymes A/S
Period End: 
31 December, 2017
Report issued on 27 March 2018 covered the following practice issues:
Pronouncements
Extended disclosure made in respect of new standards issued but not yet adopted namely IFRS 9, IFRS 15 and IFRS 16.
Change
Expansion of risk management disclosures.

Mediclinic plc Monitor

Mediclinic plc Annual Report 2017
CR Monitor Issue: 
2018/0310
Company covered: 
Mediclinic plc
Period End: 
31 March, 2017
Report issued on 20 March 2018 covered the following practice issues:
Restatement
Additional goodwill recognised following finalisation of business combination fair values.
Change
Assets and liabilities held for sale disclosed in separate lines on the face of the statement of financial position.
Change
Enhanced disclosure of financial instruments including fair value information.
Change
Disclosure of cash settled share based payment plan.
Change
Auditors' identify new area of audit focus in respect of "risk of fraud in revenue recognition".
Pronouncements
Additional disclosure on early adoption of amendment to IAS 7 "Statement of cash flows"

Novo Nordisk A/S Monitor

Novo Nordisk A/S Annual Report Year
CR Monitor Issue: 
2018/0307
Company covered: 
Novo Nordisk A/S
Period End: 
31 December, 2017
Report issued on 13 March 2018 covered the following practice issues:
Pronouncements
Extended disclosure in respect of new accounting standards issued but not yet effective including IFRS 9, IFRS 15 and IFRS 16.
Change
Structure of geographic segment information altered.
Change
Additional disclosure in respect of research and development milestone payments
New
Disclosure of social accounting policies extended.

Genus plc Monitor

Genus plc Annual Report 2017
CR Monitor Issue: 
2018/0202
Company covered: 
Genus plc
Period End: 
30 June, 2017
Report issued on 6 February 2018 covered the following practice issues:
Change
Discussion of alternative performance measures added to the financial statements.
Restatement
Change in segment reporting to reflect management structure.
Change
Financial instrument disclosures expanded to include table illustrating the ageing of trade receivables that are past due but not impaired.
Change
Identification of new risk factor in respect of "hiring and retaining talented people".
Change
Identification of new key audit matter related to "Orphan pension scheme liabilities related to the Milk Pension Fund".
Change
Presentation of audit report enhanced by inclusion of diagrams.